focus -WSS

focus

author：knowledge 2025-09-27 16:47:30 - browse：7168

light shines behind Pfizer CEO Albert Bourla as he attends a ceremony in Greece — Pfizer CEO Albert Bourla Giannis Papanikos/AP

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution.

Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen, a maker of a hot category of oncology medicines called antibody-drug conjugates. Pfizer’s shares have slumped another 9% so far this year. On Thursday, executives are holding an investor briefing to try to convince shareholders that its bet will pay off.

In an interview with STAT, Pfizer CEO Albert Bourla was insistent that the deal’s potential is being missed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Victims of gun violence feel impacts long after bullet wound

WSS

Black vets could get higher VA benefits if race not used in lung test

Primary care doctor shortage won't be solved by free med school tuition

The creative science of coining drug names

Biotech incubator Curie.Bio graduates its first startup

Novel spinal cord stimulator treats paralysis without surgery

Most antidepressants don't work on kids, teens, study finds

knowledge

focus

hotspot

Cancer drug shortages should be causing more outrage

A clever new way to fix Medicaid and graduate medical education

BioMarin wins approval for gene therapy to treat hemophilia A

Chemotherapy before breast cancer surgery might fuel metastasis

Activists slam private health insurers over coverage restrictions

Welsh Carson private equity firm escapes from FTC antitrust case

Malaria cases in Florida and Texas: Here’s what you need to know

FDA approves potent Eli Lilly obesity drug, Zepbound

New air purifier tech could be key to improving indoor air quality

GSK’s asthma push continues as drug succeeds in Phase 3 trials

hotspot

Excited delirium, Elijah McClain, and emergency physicians

Class action alleges UnitedHealth concealed DOJ probe

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

UCSF medical school apologizes for unethical prisoner experiments

Chemotherapy before breast cancer surgery might fuel metastasis

Warren pushes Witty on UnitedHealth's control over physicians

entertainment

knowledge

entertainment

Wikipedia